ICG 1

Catalog #

27752-1

$175 *

Size: 10 mg

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

ICG 1 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.

●

Synonyms

(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-(naphthalen-1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide

●

Product Data Gallery

Product Info

Storage and Usage

Citations

Purity

≥98%

Formula

C₃₃H₃₂N₄O₄

548.63 Da

Solubility

≥27.43 mg/mL in DMSO; insoluble in H2O; ≥35.47 mg/mL in EtOH with ultrasonic. For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while.

CAS Registry #

847591-62-2

Background

ICG001 selectively inhibits colon carcinoma cell lines (SW480 and HCT-116 cells) but not normal colonic epithelial cells (CCD-841Co). It is also efficacious in the Min mouse and nude mouse xenograft models of colon cancer. ICG-001 is a potent inhibitor of GBM stem cells in culture. ICG001 selectively inhibits Wnt/beta-catenin/CREB binding protein (CBP) signaling to reverses pulmonary fibrosis and ameliorate experimental dermal fibrosis in experimental models. ICG001 is currently in clinical trials for colon cancer and leukemias.

References

1. Emami KH, et al. Proc. Natl. Acad. Sci. USA 2004 Aug 24;101(34):12682-7.
2. Henderson WR Jr., et al. Proc. Natl. Acad. Sci. USA 2010 Aug 10;107(32):14309-14.
3. Beyer C, et al. Ann Rheum Dis. 2013 Jul;72(7):1255-8.

Skip to the end of the images gallery

Skip to the beginning of the images gallery

ICG 1

PRODUCTS

SERVICES

RESOURCES

COMPANY